What is Wegovy?
Wegovy contains semaglutide, a GLP-1 receptor agonist.
Regulatory source reviewedTreatment hub
semaglutide
Wegovy contains semaglutida. This page explains documented uses and safety information without deciding whether it is appropriate for an individual. Authorised uses and brand names can vary by country.
Information, not a prescription. Always check the product information and healthcare guidance that apply where you live.
Quick overview
A plain-language orientation based on regulatory documentation.
Wegovy contains semaglutide, a GLP-1 receptor agonist.
Regulatory source reviewedWegovy is authorised for chronic weight management in defined populations, with exact criteria and additional indications depending on the jurisdiction.
Check local product informationSemaglutide activates the GLP-1 receptor and affects pathways involved in appetite, food intake and glucose regulation.
Mechanism reviewedEvidence and documentation
The source links below identify the regulatory basis used for this overview.
official sources
The European public assessment page for Wegovy.
View official sourceEuropean Medicines Agency · reviewed 13 September 2026Authorised indications, warnings, adverse reactions and pharmacological information.
View official sourceEuropean Medicines Agency · reviewed 13 September 2026Drugs@FDA approval history and current US labelling. US brands and indications must be read separately from European product information.
View official sourceUS Food and Drug Administration · reviewed 13 September 2026Side effects
This summary does not replace the current patient leaflet or prescribing information in your country.
Gastrointestinal adverse reactions are described in official product information. Their wording and frequency categories must be read in the applicable label.
Official source linkedOfficial information contains warnings and precautions. Seek professional or urgent care for severe, persistent or worrying symptoms.
Check local guidanceSelf-reported effects appear separately and only as aggregates once the required sample is available.
Sample threshold appliesCommunity experiences
Moderated self-reported information, never a substitute for clinical evidence.
Available when the sample is large enough
Available when the sample is large enough
Available when the sample is large enough
Available when the sample is large enough
Each metric remains hidden until its own eligible sample reaches the publication threshold.
Treatment Observatory
Longitudinal summaries use the same approved data source as the Spanish site.
Planned time point
This view will appear only when the defined threshold is met.
Planned time point
This view will appear only when the defined threshold is met.
Planned time point
This view will appear only when the defined threshold is met.
Planned time point
This view will appear only when the defined threshold is met.
Small or unsuitable samples are not turned into trends.
Questions
General information only.
No. It does not diagnose, prescribe or provide an individual recommendation.
Regulators approve medicines and brand indications within their own jurisdictions. Use the current local product information.
As moderated, self-reported accounts. They do not prove that a medicine caused an outcome.
Community participation
Positive, negative and neutral experiences—current or completed—follow the same moderation criteria.
Share my experienceSubmissions remain pending review and are never published automatically.